Asunto(s)
Anticuerpos Antivirales , Síndrome Post Agudo de COVID-19 , Humanos , Anticuerpos Antivirales/efectos adversos , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Síndrome Post Agudo de COVID-19/sangre , Síndrome Post Agudo de COVID-19/etiología , Síndrome Post Agudo de COVID-19/inmunología , Síndrome Post Agudo de COVID-19/fisiopatología , SARS-CoV-2/inmunología , Animales , RatonesRESUMEN
BACKGROUND AND OBJECTIVES: Clinical manifestations of coronavirus disease 2019 (COVID-19) often persist after acute disease resolution. Underlying molecular mechanisms are unclear. The objective of this original article was to longitudinally measure plasma levels of markers of the innate immune response to investigate whether they associate with and predict post-COVID symptomatology. METHODS: Adult patients with previous severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during the first pandemic wave who underwent the 6-month multidisciplinary follow-up were included. Plasma levels of pentraxin 3 (PTX3), the complement components C3a and C5a, and chitinase-3 like-protein-1 (CHI3L1) were measured at hospital admission during acute disease (baseline) and at 1 and 6 months after hospital discharge. Associations with post-COVID-19 sequelae at 6 months were investigated using descriptive statistic and multiple regression models. RESULTS: Ninety-four COVID-19 patients were included. Baseline PTX3, C5a, C3a, and CHI3L1 did not predict post-COVID-19 sequelae. The extent of the reduction of PTX3 over time (delta PTX3) was associated with lower depressive and anxiety symptoms at 6 months (both p < 0.05). When entering sex, age, need for intensive care unit or non-invasive ventilation during hospital stay, psychiatric history, and baseline PTX3 as nuisance covariates into a generalized linear model (GLM), the difference between baseline and 6-month PTX3 levels (delta PTX3) significantly predicted depression (χ2 = 4.66, p = 0.031) and anxiety (χ2 = 4.68, p = 0.031) at 6 months. No differences in PTX3 levels or PTX3 delta were found in patients with or without persistent or new-onset other COVID-19 symptoms or signs at 6 months. Plasma levels of C3a, C5a, and CHI3L1 did not correlate with PTX3 levels at either time point and failed to associate with residual or de novo respiratory or systemic clinical manifestations of the disease at 6 months. CONCLUSIONS: A lower reduction of plasma PTX3 after acute COVID-19 associates with the presence of depression and anxiety, suggesting an involvement of inflammation in post-COVID-19 psychopathology and a potential role of PTX3 as a biomarker.
Asunto(s)
Ansiedad , Biomarcadores , Proteína C-Reactiva , COVID-19 , Síndrome Post Agudo de COVID-19 , Componente Amiloide P Sérico , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ansiedad/sangre , Ansiedad/diagnóstico , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Proteína C-Reactiva/análisis , COVID-19/sangre , COVID-19/complicaciones , Depresión/sangre , Estudios de Seguimiento , Estudios Longitudinales , Síndrome Post Agudo de COVID-19/sangre , Síndrome Post Agudo de COVID-19/diagnóstico , Componente Amiloide P Sérico/análisis , Componente Amiloide P Sérico/metabolismoRESUMEN
Long Covid is a debilitating condition of unknown etiology. We performed multimodal proteomics analyses of blood serum from COVID-19 patients followed up to 12 months after confirmed severe acute respiratory syndrome coronavirus 2 infection. Analysis of >6500 proteins in 268 longitudinal samples revealed dysregulated activation of the complement system, an innate immune protection and homeostasis mechanism, in individuals experiencing Long Covid. Thus, active Long Covid was characterized by terminal complement system dysregulation and ongoing activation of the alternative and classical complement pathways, the latter associated with increased antibody titers against several herpesviruses possibly stimulating this pathway. Moreover, markers of hemolysis, tissue injury, platelet activation, and monocyte-platelet aggregates were increased in Long Covid. Machine learning confirmed complement and thromboinflammatory proteins as top biomarkers, warranting diagnostic and therapeutic interrogation of these systems.
Asunto(s)
Activación de Complemento , Proteínas del Sistema Complemento , Síndrome Post Agudo de COVID-19 , Proteoma , Tromboinflamación , Humanos , Proteínas del Sistema Complemento/análisis , Proteínas del Sistema Complemento/metabolismo , Síndrome Post Agudo de COVID-19/sangre , Síndrome Post Agudo de COVID-19/complicaciones , Síndrome Post Agudo de COVID-19/inmunología , Tromboinflamación/sangre , Tromboinflamación/inmunología , Biomarcadores/sangre , Proteómica , Masculino , Femenino , Adulto Joven , Adulto , Persona de Mediana Edad , AncianoRESUMEN
Links between the complement and coagulation systems could lead to Long Covid therapies.
Asunto(s)
Coagulación Sanguínea , Proteínas del Sistema Complemento , Síndrome Post Agudo de COVID-19 , Humanos , Coagulación Sanguínea/inmunología , Proteínas del Sistema Complemento/análisis , Proteínas del Sistema Complemento/inmunología , Síndrome Post Agudo de COVID-19/sangre , Síndrome Post Agudo de COVID-19/inmunologíaAsunto(s)
Síndrome Post Agudo de COVID-19 , SARS-CoV-2 , Serotonina , Humanos , COVID-19/complicaciones , COVID-19/virología , Síndrome Post Agudo de COVID-19/sangre , Síndrome Post Agudo de COVID-19/etiología , Síndrome Post Agudo de COVID-19/virología , SARS-CoV-2/aislamiento & purificación , Serotonina/análisis , Carga ViralRESUMEN
Post-acute sequelae of COVID-19 (PASC, "Long COVID") pose a significant global health challenge. The pathophysiology is unknown, and no effective treatments have been found to date. Several hypotheses have been formulated to explain the etiology of PASC, including viral persistence, chronic inflammation, hypercoagulability, and autonomic dysfunction. Here, we propose a mechanism that links all four hypotheses in a single pathway and provides actionable insights for therapeutic interventions. We find that PASC are associated with serotonin reduction. Viral infection and type I interferon-driven inflammation reduce serotonin through three mechanisms: diminished intestinal absorption of the serotonin precursor tryptophan; platelet hyperactivation and thrombocytopenia, which impacts serotonin storage; and enhanced MAO-mediated serotonin turnover. Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory. These findings provide a possible explanation for neurocognitive symptoms associated with viral persistence in Long COVID, which may extend to other post-viral syndromes.
Asunto(s)
Síndrome Post Agudo de COVID-19 , Serotonina , Humanos , COVID-19/complicaciones , Progresión de la Enfermedad , Inflamación , Síndrome Post Agudo de COVID-19/sangre , Síndrome Post Agudo de COVID-19/patología , Serotonina/sangre , VirosisRESUMEN
BACKGROUND: Previous studies have reported Blood type O to confer a lower risk of SARS-CoV-2 infection, while secretor status and other blood groups have been suspected to have a similar effect as well. STUDY DESIGN AND METHODS: To determine whether any other blood groups influence testing positive for SARS-CoV-2, COVID-19 severity, or prolonged COVID-19, we used a large cohort of 650,156 Danish blood donors with varying available data for secretor status and blood groups ABO, Rh, Colton, Duffy, Diego, Dombrock, Kell, Kidd, Knops, Lewis, Lutheran, MNS, P1PK, Vel, and Yt. Of these, 36,068 tested positive for SARS-CoV-2 whereas 614,088 tested negative between 2020-02-17 and 2021-08-04. Associations between infection and blood groups were assessed using logistic regression models with sex and age as covariates. RESULTS: The Lewis blood group antigen Lea displayed strongly reduced SARS-CoV-2 susceptibility OR 0.85 CI[0.79-0.93] p < .001. Compared to blood type O, the blood types B, A, and AB were found more susceptible toward infection with ORs 1.1 CI[1.06-1.14] p < .001, 1.17 CI[1.14-1.2] p < .001, and 1.2 CI[1.14-1.26] p < .001, respectively. No susceptibility associations were found for the other 13 blood groups investigated. There was no association between any blood groups and COVID-19 hospitalization or long COVID-19. No secretor status associations were found. DISCUSSION: This study uncovers a new association to reduced SARS-CoV-2 susceptibility for Lewis type Lea and confirms the previous link to blood group O. The new association to Lea could be explained by a link between mucosal microbiome and SARS-CoV-2.
Asunto(s)
Antígenos de Grupos Sanguíneos , COVID-19 , Síndrome Post Agudo de COVID-19 , Humanos , Sistema del Grupo Sanguíneo ABO , Antígenos de Grupos Sanguíneos/genética , Estudios de Cohortes , COVID-19/sangre , COVID-19/genética , Síndrome Post Agudo de COVID-19/sangre , Síndrome Post Agudo de COVID-19/genética , SARS-CoV-2 , Predisposición Genética a la EnfermedadRESUMEN
The diagnosis of postacute sequelae of coronavirus disease 2019 (PASC) poses an ongoing medical challenge. To identify biomarkers associated with PASC we analyzed plasma samples collected from PASC and coronavirus disease 2019 patients to quantify viral antigens and inflammatory markers. We detect severe acute respiratory syndrome coronavirus 2 spike predominantly in PASC patients up to 12 months after diagnosis.